Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Inks Screening Deal with SuperGen

NEW YORK (GenomeWeb News) – Horizon Discovery today said that it has inked an agreement with SuperGen, under which it will provide screening services for the biopharmaceutical firm's drug candidates using its X-MAN technology.

The Cambridge, UK-based firm said that the deal covers the screening of lead compounds on a wide panel of human isogenic cell lines that comprise target genotypes of interest to SuperGen. The X-MAN technology may enable SuperGen to obtain information about the selectivity and mode-of-action of its compounds using model in vitro systems, said Horizon.

Under terms of the alliance, SuperGen will pay Horizon undisclosed fees. The partners expect to begin the collaboration this month.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.